Novartis Eyes China Community Hospital Market
This article was originally published in PharmAsia News
China's health care reform which aims to maintain public health service is set to impact pharmaceutical MNCs. Foreign corporations are looking at community hospitals as a potential market, and Novartis has established a special institution that collaborates with community hospitals. The head of Novartis China believes local pharmaceutical companies will benefit more than MNCs from the reform, but the latter can still participate in basic health care with their generic drugs. China's immunity program expansion also brings business opportunities. Novartis is discussing with China National Biotec Group, China's key state vaccine manufacturer, on possible cooperation. (Click here for more - Chinese Language)
You may also be interested in...
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.